NDASUBCUTANEOUSSOLUTION, EXTENDED RELEASEPriority Review
Approved
May 2023
Lifecycle
Growth
Competitive Pressure
0/100
Clinical Trials
20
Mechanism of Action
Partial Opioid Agonists
Pharmacologic Class:
Partial Opioid Agonist
Indications (1)
Clinical Trials (5)
Acceptability and Feasibility of Extended-Release Subcutaneous Buprenorphine on a Mobile Pharmacy Clinic
Started Mar 2026
60 enrolled
Opioid Use Disorder
Evaluation of Tirzepatide as an Adjunct to Buprenorphine for the Treatment of Opioid Use Disorder
Started Dec 2025
Drug-drug Interaction Study of Bemnifosbuvir/Ruzasvir (BEM/RZR) and Buprenorphine/Naloxone or Methadone
Started Dec 2025
A Study to Test Whether BI 1356225 Improves Impulsive Behavior in People With Opioid Use Disorder Who Are Taking Buprenorphine
Started Jan 2025
60 enrolled
Opioid Use Disorder
Evaluation of Buprenorphine Extended-Release Subcutaneous Injection at Alternative Injection Locations
Started Mar 2023
132 enrolled
Opioid Use Disorder
Loss of Exclusivity
LOE Date
Jul 26, 2032
77 months away
Patent Expiry
Jul 26, 2032
Exclusivity Expiry
May 23, 2026